DYN – dyne therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Raymond James to a "strong-buy" rating.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $46.00 price target on the stock.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]
Form 4 Dyne Therapeutics, Inc. For: Dec 11 Filed by: Beskrovnaya Oxana
Form 4 Dyne Therapeutics, Inc. For: Dec 11 Filed by: Scalzo Richard William
Form 144 Dyne Therapeutics, Inc. Filed by: HIGH SUSANNA GATTI
Form 144 Dyne Therapeutics, Inc. Filed by: Beskrovnaya Oxana
Form 144 Dyne Therapeutics, Inc. Filed by: Scalzo Richard William
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.